The invention relates to a pharmaceutical composition comprising (i) a renininhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic and to amethod of treatment of a condition or a disease selected from the groupconsisting of hypertension, heart failure such as (acute and chronic)congestive heart failure, left ventricular dysfunction and hypertrophiccardiomyopathy, diabetic cardiac myopathy, supraventricular and ventriculararrhythmias, atrial fibrillation, atrial flutter, detrimental vascularremodeling, myocardial infarction and its sequelae, atherosclerosis, angina(whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism,primary and secondary pulmonary hypertension, renal failure conditions, suchas diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renalfibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, andalso renal vascular hypertension, diabetic retinopathy, the management ofother vascular disorders, such as migraine, peripheral vascular disease,Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such asAlzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibroticdiseases resulting from accumulation of excess extracellular matrix induced byTGF, and proliferative diseases of smooth muscle cells, including uterinefibroids comprising administering a therapeutically effective amount of saidpharmaceutical composition to a mammal in need of such treatment.
